Lymphoma Medical Services in China

Lymphoma is a heterogeneous group of malignant neoplasms originating from lymphoid tissue—primarily B cells, but also T cells and natural killer (NK) cells—within the immune system. It is broadly classified into two major categories: Hodgkin lymphoma (HL), characterized by the presence of Reed-Sternberg cells, and non-Hodgkin lymphoma (NHL), which encompasses over 90 distinct subtypes (e.g., diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma) with varying biological behaviors, clinical courses, and therapeutic responses. Pathogenesis involves cumulative genetic alterations—including chromosomal translocations (e.g., BCL2 in follicular lymphoma), somatic hypermutation errors, epigenetic dysregulation, and chronic antigenic stimulation—that disrupt normal lymphocyte proliferation, differentiation, and apoptosis. Immune dysfunction (e.g., HIV infection, post-transplant immunosuppression) and persistent viral infections (EBV, HTLV-1, HCV) further contribute to malignant transformation. Epidemiologically, lymphoma is the seventh most common cancer globally and the most frequent hematologic malignancy. In China, age-standardized incidence rates are approximately 5.2 per 100,000 for NHL and 0.7 per 100,000 for HL, with NHL incidence rising steadily—particularly among adults aged 60–75 years. Key risk factors include advanced age, male sex, autoimmune disorders (e.g., Sjögren’s syndrome, rheumatoid arthritis), immunosuppressive therapy, certain occupational exposures (e.g., pesticides, benzene), and familial predisposition. Lymphoma profoundly impacts quality of life: patients commonly experience debilitating fatigue, night sweats, unexplained weight loss, pruritus, and recurrent infections; psychological burden—including anxiety, depression, and treatment-related uncertainty—is prevalent; and long-term survivors may face late effects such as secondary cancers, cardiovascular toxicity, infertility, and neurocognitive deficits. Treatment-related side effects (e.g., chemotherapy-induced neuropathy, immunotherapy-related cytokine release syndrome) further compromise functional status and daily living activities. Early diagnosis remains challenging due to nonspecific symptoms mimicking benign conditions (e.g., mononucleosis, chronic fatigue syndrome), underscoring the need for heightened clinical suspicion and timely referral to hematology specialists for comprehensive evaluation—including biopsy, flow cytometry, molecular profiling, and PET-CT staging.

Lymphoma is a heterogeneous group of hematologic malignancies originating from lymphoid tissue, broadly classified into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), with NHL accounting for approximately 90% of cases. Treatment strategies are highly individualized, guided by histopathologic subtype, disease stage, molecular and genetic profiling, patient age, performance status, and comorbidities. In the Department of Hematology, management integrates risk-adapted, evidence-based approaches grounded in international guidelines (e.g., NCCN, ESMO, Lugano Classification) while incorporating regionally validated protocols and innovations.

Conservative treatment—often termed 'active surveillance' or 'watch-and-wait'—is reserved exclusively for select indolent lymphomas demonstrating minimal tumor burden and no B symptoms (fever >38°C, drenching night sweats, weight loss >10% in 6 months), organ dysfunction, cytopenias, or rapidly progressive disease. This approach is most commonly applied to asymptomatic early-stage follicular lymphoma (FL), marginal zone lymphoma (MZL), or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). During surveillance, patients undergo clinical evaluation every 2–3 months, complete blood counts, lactate dehydrogenase (LDH), beta-2-microglobulin, and imaging (e.g., contrast-enhanced CT or PET/CT) every 6–12 months. The rationale is to defer cytotoxic therapy until clinically indicated, thereby avoiding unnecessary toxicity without compromising overall survival—a strategy supported by long-term data from the FOLL05 and PRIMA trials.

Pharmacotherapy constitutes the cornerstone of lymphoma management. For aggressive B-cell lymphomas—including diffuse large B-cell lymphoma (DLBCL)—first-line therapy remains R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), administered every 21 days for six cycles. Rituximab, a CD20-targeted monoclonal antibody, significantly improves progression-free and overall survival across multiple subtypes. In high-risk or relapsed/refractory DLBCL, intensified regimens (e.g., R-DHAP, R-ICE) followed by autologous stem cell transplantation (ASCT) are standard. Novel agents include polatuzumab vedotin (anti-CD79b antibody-drug conjugate), tafasitamab (Fc-enhanced anti-CD19), and bispecific T-cell engagers (e.g., glofitamab, epcoritamab). For mantle cell lymphoma (MCL), frontline options include bendamustine-rituximab (BR), R-CHOP, or cytarabine-containing regimens (e.g., R-DHAC), with ibrutinib or acalabrutinib (BTK inhibitors) used in relapse or as maintenance. Follicular lymphoma benefits from rituximab maintenance post-induction, and lenalidomide-rituximab (R²) has emerged as an effective chemo-free option. In HL, ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) remains first-line; for advanced or refractory disease, brentuximab vedotin (anti-CD30 ADC) and PD-1 inhibitors (nivolumab, pembrolizumab) have transformed outcomes. Supportive medications—including granulocyte colony-stimulating factor (G-CSF), antifungals, antivirals (e.g., acyclovir for herpes prophylaxis), and growth factor support—are routinely integrated to mitigate infection risk and hematologic toxicity.

Surgical intervention plays a very limited role in lymphoma management. Lymph node biopsy—typically excisional—is essential for definitive diagnosis and immunophenotyping but is diagnostic, not therapeutic. Rare exceptions include localized gastrointestinal MALT lymphoma with Helicobacter pylori–positive gastric involvement, where surgical resection may be considered if endoscopic eradication fails and there is evidence of transformation or perforation risk. Similarly, isolated cutaneous lymphomas unresponsive to radiotherapy or systemic therapy may undergo wide local excision. Surgery is contraindicated for staging or debulking in systemic disease, as it offers no survival benefit and risks complications including immunosuppression-related wound dehiscence and infection.

Treatment in China offers distinct advantages rooted in infrastructure, innovation, and integration. First, China’s national lymphoma registry and multi-center clinical trial networks (e.g., CHOP, C-LYMPH) enable rapid accrual for phase II/III trials evaluating novel agents—including domestically developed CAR-T therapies (e.g., relmacabtagene autoleucel for relapsed/refractory B-cell lymphoma, approved by NMPA in 2023). Second, cost-effective access to biosimilar rituximab and generic chemotherapy agents reduces financial toxicity, with many regimens covered under the National Reimbursement Drug List (NRDL). Third, integrative oncology programs—standardized across Tier-3 hospitals—combine evidence-based traditional Chinese medicine (TCM) adjuncts (e.g., Jianpi Jiedu decoction for chemotherapy-induced myelosuppression) with rigorous pharmacovigilance and outcome tracking. Fourth, centralized pathology review through the Chinese Lymphoma Working Group ensures diagnostic accuracy and molecular subtyping consistency, minimizing inter-institutional variability. Finally, digital health platforms facilitate remote monitoring, AI-assisted PET/CT interpretation, and real-time adverse event reporting—enhancing continuity of care across urban and rural settings.

Recovery and long-term follow-up require multidimensional support. Patients should undergo structured survivorship planning beginning at treatment completion: physical assessments (including cardiac echo for anthracycline-exposed patients), thyroid function tests (post-radiation), and screening for secondary malignancies (e.g., breast, lung, skin cancers). Vaccination status must be reviewed—non-live vaccines (e.g., influenza, pneumococcal conjugate, COVID-19 mRNA) should be administered ≥6 months post-chemotherapy or ASCT; live vaccines are contraindicated for ≥24 months. Lifestyle counseling emphasizes smoking cessation, moderate aerobic exercise (150 min/week), Mediterranean-style nutrition rich in antioxidants and fiber, and avoidance of immunosuppressive herbal supplements without hematologist approval. Psychosocial support—including cognitive behavioral therapy and peer-led lymphoma support groups—is strongly recommended, given elevated rates of anxiety, depression, and cancer-related fatigue. Regular surveillance includes CBC, LDH, and imaging every 3–6 months for first two years, then annually up to five years; PET/CT is reserved for suspected relapse. Patients receiving BTK inhibitors require ongoing cardiovascular monitoring (BP, ECG), while those on lenalidomide need monthly CBCs and venous thromboembolism prophylaxis. Finally, fertility preservation counseling should occur prior to alkylator-based regimens, especially in adolescents and young adults. With comprehensive, personalized, and longitudinally coordinated care, 5-year overall survival exceeds 90% for early-stage HL and 70–80% for localized DLBCL—underscoring the importance of timely referral to specialized hematology centers.